Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Chronic Obstructive Lung Disease Clinical Trials

A listing of Chronic Obstructive Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (93) clinical trials

You must be 40 years of age or older You must have a diagnosis of COPD for at least a year You must currently be treating your COPD with a daily medication for at least 8 weeks prior to starting the study You must be a current or former smoker ...

Phase N/A

This study will be testing an investigational medication for COPD Eligibility Criteria: -Age 40 years or older -Diagnosis of COPD for at least 12 months -Current Smoker or Ex-Smoker -Other criteria may apply Other Details: Qualified volunteers will receive study medication, study supplies and any study required testing at no ...

Phase

We are looking for individuals to participate in a research study to determine the safety and efficacy of an investigational medication. Eligibility Criteria: If you are: - 40 years of age or older - are a previous or current smoker - have a diagnosis of chronic obstructive pulmonary disease (COPD) ...

Phase N/A

Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease

Patients admitted to Department of Internal Medicine M, Glostrup University hospital, with Chronic Obstructive Pulmonary Disease (COPD) are evaluated with regard to early follow-up by a specialized nurse in the home after discharge. Eligible patients receive education about disease management. The intervention is evaluated by comparing the number of readmissions ...

Phase N/A

Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease

In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown. Airway ...

Phase

Early Pulmonary Rehabilitation Following Acute COPD Exacerbation

Background: Chronic obstructive pulmonary disease (COPD), also sometimes known as chronic asthma, bronchitis or emphysema, is an important health problem. Many people with COPD are admitted into hospital with a worsening of their symptoms, known as an exacerbation. Hospitalisations for acute exacerbations of chronic obstructive pulmonary disease (COPD) are a ...

Phase

Sequential Endoscopic Lung Volume Reduction

Patients with heterogenous emphysema undergo ELVR, target lobe is the upper lobe right. After 6 weeks the middle lobe will be block too. Follow-up period 6 months Primary end points: FEV 1, 6-Minute walk test Secondary endpoints. Safety, Symptom scores Number of patients planned 30

Phase

Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering drugs that decrease mortality from cardiovascular disease and ...

Phase

LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure

Long-term oxygen treatment (LTOT) improves survival of COPD patients with severe hypoxemia . The improved survival was proven in COPD patients with severe chronic hypoxemia (PaO2< or = 55 mmHg), providing oxygen was delivered for = or >15 hours/day. Since then, > 15 hours/day LTOT has become the standard treatment ...

Phase

Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial

What is the problem to be addressed? Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular events. Indeed, ischemic heart disease is one of the leading causes of mortality and hospitalization among patients with mild to moderate COPD. For every 10% decrease in forced expiratory volume ...

Phase